About Me
Driven by an insatiable curiosity, I have long been dedicated to understanding the mechanisms of complex systems. This passion led me to pursue a medical degree, which naturally aligned with my thirst for knowledge, fascination with the intricacies of the human body, and deep compassion for others.
Throughout medical school, I encountered the stark reality that many diseases remain without known cures or established causes, which only intensified my commitment to the field of medicine. After earning my PhD in cancer genetics from Stony Brook University, I expanded my knowledge by gaining valuable insights through research in both academic and industry settings. These experiences solidified my desire to merge clinical practice with research, enabling me to provide compassionate and cutting-edge care to patients confronting hematologic and oncologic challenges.
At NYU Langone and Bellevue Hospital Center, I care for patients with both benign and malignant hematologic disorders, as well as those with genitourinary cancers, including prostate, kidney, bladder, and testicular cancers.
I believe that every patient is unique, and their care should reflect that individuality. This drives me to take a personalized approach to treatment, tailoring each plan to the specific characteristics of the patient and their disease. Our patient-centered philosophy extends beyond simply treating cancer; we are committed to addressing the emotional, psychological, and social dimensions of each individual’s experience. When patients choose our care, they gain not only access to highly skilled specialists but also to the latest advancements in research and cutting-edge clinical trials. Together, we provide a holistic, compassionate, and innovative approach to healing—one that strives to make a lasting impact on both the science of medicine and the lives of those we treat.
Conditions and Treatments
Conditions
- acute myelogenous leukemia (AML)
- aids-related malignancies
- anemia
- bladder cancer
- central nervous system lymphomas (CNS)
- chronic myelogenous leukemia (CML)
- cutaneous t-cell lymphoma
- diffuse large b-cell lymphoma
- essential thrombocythemia (ET)
- female germ cell tumor
- hodgkin lymphoma
- kidney cancer
- male germ cell tumor
- multiple myeloma
- myelodysplastic syndromes (MDS)
- myelofibrosis
- myeloproliferative disorder
- non-hodgkin lymphoma
- polycythemia vera
- prostate cancer
- sickle cell anemia
- testicular cancer
- thrombocytopenia
- thrombosis
- ureter cancer
Learn more about conditions we treat at NYU Langone:
Acute Myeloid Leukemia , Leukemia , AIDS-Related Lymphoma , Bladder Cancer , Primary Central Nervous System Lymphoma , Chronic Myelogenous Leukemia , Cutaneous T-Cell Lymphoma , Hodgkin Lymphoma , Kidney Cancer , Multiple Myeloma , Myelodysplastic Syndromes , Myeloproliferative Disorders , Non-Hodgkin Lymphoma , Prostate Cancer , Testicular CancerCredentials
Positions
- Clinical Assistant Professor, Department of Medicine at NYU Grossman School of Medicine
- Site Director, Hematology and Medical Oncology Fellowship, Bellevue Cancer Center
- Director, Research, Bellevue Cancer Center
Board Certifications
- American Board of Internal Medicine (Medical Oncology), 2020
- American Board of Internal Medicine (Hematology), 2019
- American Board of Internal Medicine - Internal Medicine, 2017
Education and Training
- Fellowship, Montefiore Medical Center/Albert Einstein College of Medicine, Hematology & Medical Oncology, 2019
- Residency, Montefiore Medical Center/Albert Einstein College of Medicine, Internal Medicine, 2016
- PhD from Stony Brook University, 2008
- MD from Carol Davila University of Medicine and Pharmacy, 2003
Is this your profile?
Edit profileInsurance Plans Accepted
Please call the office for information about accepted insurance plans.
Cristian C. Papazoglu Statescu, MD, PhD does not accept insurance.
Research Academic Contact
Academic office
462 First Avenue, OBV-C&D Building
5th Floor, 556
New York, NY 10016
Phone
Fax
Clinical Trials and Research Studies
-
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence
-
A Phase II Study of Ribociclib And Endocrine Treatment of Physician s Choice for Locoregional Recurrent Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
-
SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing FirstLine Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression =50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression
Publications
-
Aminov, Sarah; Giricz, Orsi; Melnekoff, David T; Sica, R Alejandro; Polishchuk, Veronika; Papazoglu, Cristian; Yates, Bonnie; Wang, Hao-Wei; Sahu, Srabani; Wang, Yanhua; Gordon-Mitchell, Shanisha; Leshchenko, Violetta V; Schinke, Carolina; Pradhan, Kith; Aluri, Srinivas; Sohn, Moah; Barta, Stefan K; Agarwal, Beamon; Goldfinger, Mendel; Mantzaris, Ioannis; Shastri, Aditi; Matsui, William; Steidl, Ulrich; Brody, Joshua D; Shah, Nirali N; Parekh, Samir; Verma, Amit
Journal of clinical investigation. 2024 Feb 20; 134(8):
-
Bhatt, Ahan; Papazoglu, Cristian; Shukla, Pratibha
[Zhong ji yi kan] = [Medicine for intermediate groups]. 2023; 41(16_suppl):
-
Zhang, Hailan; Fraser, Stuart T; Papazoglu, Cristian; Hoatlin, Maureen E; Baron, Margaret H
Stem cells. 2009 Dec ; 27(12):2884-95